The invention provides a start-up method for a process for the preparation of glycols from a starting material comprising one or more saccharides in the presence of hydrogen and a catalyst system comprising one or more retro-aldol catalysts comprising tungsten and one or more catalytic species suitable for hydrogenation in a reactor, said method comprising introducing the one or more retro-aldol catalysts to the reactor whilst also in the presence of one or more agents suitable to suppress tungsten precipitation.

Disclosed are a catalyst for synergistic control of oxynitride and mercury and a method for preparing the same. The catalyst includes the following components by mass percentage: a carrier: TiO2 72%-98.6%, active components: V2O5 0.1%-5%, WO3 1%-10%, Cr2O3 0.1%-5% and Nb2O5 0.1%-5%, and a co-catalyst of 0.1%-3%. The present invention can be used for reducing the oxynitrides in a flue gas, meanwhile oxidizing zero-valent mercury into bivalent mercury and then controlling the reactions, has relatively high denitration performance and also has high mercury oxidation performance; compared with current commercial SCR catalysts, the mercury oxidation rate of the catalyst is improved to a great extent, which can adapt to the requirements for mercury removal in China's coal-fired power plants, the conversion rate of SO2/SO3 is relatively low, and the catalyst has a better anti-poisoning ability, and is a new catalyst with a low cost and high performance.

Disclosed are a catalyst for synergistic control of oxynitride and mercury and a method for preparing the same. The catalyst includes the following components by mass percentage: a carrier: TiO2 72%-98.6%, active components: V2O5 0.1%-5%, WO3 1%-10%, Cr2O3 0.1%-5% and Nb2O5 0.1%-5%, and a co-catalyst of 0.1%-3%. The present invention can be used for reducing the oxynitrides in a flue gas, meanwhile oxidizing zero-valent mercury into bivalent mercury and then controlling the reactions, has relatively high denitration performance and also has high mercury oxidation performance; compared with current commercial SCR catalysts, the mercury oxidation rate of the catalyst is improved to a great extent, which can adapt to the requirements for mercury removal in China's coal-fired power plants, the conversion rate of SO2/SO3 is relatively low, and the catalyst has a better anti-poisoning ability, and is a new catalyst with a low cost and high performance.

The present invention provides a catalyst comprising a transition metal, an inorganic support, a zeolite, and a layered double hydroxide. Using of the catalyst according to the present invention in an olefin production process exhibits high activity and high selectivity with decreased deactivation rate, therefore longer reaction cycle can be performed and catalyst life is prolonged.

The present invention provides a catalyst comprising a transition metal, an inorganic support, a zeolite, and a layered double hydroxide. Using of the catalyst according to the present invention in an olefin production process exhibits high activity and high selectivity with decreased deactivation rate, therefore longer reaction cycle can be performed and catalyst life is prolonged.

A method of reducing a gaseous carbon oxide includes reacting a carbon oxide with a gaseous reducing agent in the presence of a non-ferrous catalyst. The reaction proceeds under conditions adapted to produce solid carbon of various allotropes and morphologies, the selective formation of which can be controlled by means of controlling reaction gas composition and reaction conditions including temperature and pressure. A method for utilizing a non-ferrous catalyst in a reactor includes placing the catalyst in a suitable reactor and flowing reaction gases comprising a carbon oxide with at least one gaseous reducing agent through the reactor where, in the presence of the catalyst, at least a portion of the carbon in the carbon oxide is converted to solid carbon and a tail gas mixture containing water vapor.

A method of reducing a gaseous carbon oxide includes reacting a carbon oxide with a gaseous reducing agent in the presence of a non-ferrous catalyst. The reaction proceeds under conditions adapted to produce solid carbon of various allotropes and morphologies, the selective formation of which can be controlled by means of controlling reaction gas composition and reaction conditions including temperature and pressure. A method for utilizing a non-ferrous catalyst in a reactor includes placing the catalyst in a suitable reactor and flowing reaction gases comprising a carbon oxide with at least one gaseous reducing agent through the reactor where, in the presence of the catalyst, at least a portion of the carbon in the carbon oxide is converted to solid carbon and a tail gas mixture containing water vapor.

The present invention relates to catalyst comprising at least one transition metal selected from Group VIA and Group VITA metals and a support containing a mixture of 0.1 to 60 percent by weight of zeolite, based on total weight of the support, with at least one other inorganic or organic material, wherein the at least one other inorganic or organic material is selected from silicon dioxide, titanium dioxide, zirconium dioxide and activated carbon, preferably silicon dioxide; and a process for olefin metathesis utilizing that catalyst.

The present invention relates to catalyst comprising at least one transition metal selected from Group VIA and Group VITA metals and a support containing a mixture of 0.1 to 60 percent by weight of zeolite, based on total weight of the support, with at least one other inorganic or organic material, wherein the at least one other inorganic or organic material is selected from silicon dioxide, titanium dioxide, zirconium dioxide and activated carbon, preferably silicon dioxide; and a process for olefin metathesis utilizing that catalyst.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.